Biocon Biologics, a subsidiary of Biocon, has been recognized for the eighth consecutive year as an Asia IP Elite for 2024 by IAM (Intellectual Asset Management). This prestigious accolade highlights Biocon Biologics' dedication to innovation and its robust intellectual property strategy, which plays a crucial role in enabling access to affordable biosimilar therapies globally.

Asia IP Elite for 2024 is the world’s leading Intellectual Property (IP) publication.